You are here

Virion Solvent Treatment for SARS Vaccine Preparation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI060267-01
Agency Tracking Number: AI060267
Amount: $100,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2004
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
LIPID SCIENCES, INC. 7068 KOLL CENTER PKY, STE 401
PLEASANTON, CA 94568
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 LYNN SUER
 (650) 859-3093
 LYNN.SUER@SRI.COM
Business Contact
Phone: (925) 249-4050
Research Institution
 SRI INTERNATIONAL
 
SRI INTERNATIONAL
MENLO PARK, CA 94025
United States

 Domestic Nonprofit Research Organization
Abstract

DESCRIPTION (provided by applicant): Lipid Sciences, Inc., proposes to use its proprietary solvent treatment technology to develop a modified SARS viral particle to use as a prophylactic vaccine. SARS has the potential to reemerge with greater force at any time; therefore, a preventative vaccine would be highly desirable to protect both global health and economies. Our vaccine production method potentially could provide improved antigenicity and safety, general applicability to all types of lipid-enveloped viruses, simultaneous applicability to many strains of a single virus type, and the potential to prepare patient specific vaccines.

We have previously demonstrated that our solvent treatment method increases humoral and cellular response to SIV in a mouse model, and is protective in a duck hepatitis B model. We will test the ability of solvent-treated virus, which has been subsequently subjected to chemical inactivation, to raise neutralizing antibodies and produce a cellular immune response in mice. Specific Aims are (1) Optimize proprietary solvent treatment method for SARS virus based on previous virus experience and evaluate native viral protein structure and viral envelope changes post treatment, and (2) Test ability of solvent and chemically treated virions to produce an immune response in mice, and test for production of neutralizing antibodies and cellular response.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government